Pull to refresh
Logo
Telix acquires isotope maker ITM in deal worth up to $2.35 billion

Telix acquires isotope maker ITM in deal worth up to $2.35 billion

Money Moves

The merger adds a late-stage rival to Novartis' Lutathera and control of the world's largest lutetium-177 supply network

Today: Telix announces $1.65 billion ITM merger

Overview

Updated 1 hour ago

Telix Pharmaceuticals, an Australian maker of cancer imaging and treatment agents, agreed on September 21 to buy German isotope producer ITM Isotope Technologies Munich. The deal is worth up to $2.35 billion all-in, with $1.65 billion paid upfront, most of it in Telix shares.

The purchase secures the world's largest supply network for lutetium-177, the isotope behind Novartis' blockbuster prostate cancer drug Pluvicto. It also adds ITM-11, a late-stage therapy for neuroendocrine tumors that targets the same market as Novartis' Lutathera. Analysts at five banks rate Telix a Buy, with target prices 27% to 79% above the current share price.

Why it matters

This deal hands Telix control of the isotope supply chain its larger rivals depend on, reshaping competition in a $41 billion nuclear medicine market.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$2.35B
Maximum deal value including milestone payments
Composed of $1.65 billion upfront plus up to $700 million contingent on ITM-11 approvals and sales.
$1.65B
Upfront consideration
About $1.25 billion paid in Telix shares at $11.84 each, released as Nasdaq ADRs after escrow.
$273M
ITM's 2025 revenue
Annual revenue from radioisotope sales across 65 countries to more than 400 destinations weekly.
40%
ITM revenue compound annual growth rate, 2021–2025
Growth driven by rising global demand for targeted radionuclide therapy.
76.3%
Telix shareholder ownership after closing
ITM shareholders would hold approximately 23.7% of the combined company.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

2004 September 2026

4 events Latest: Today
Tap a bar to jump to that date
  1. Telix announces $1.65 billion ITM merger

    Today Business

    Telix agrees to buy ITM with $1.65 billion upfront and up to $700 million in ITM-11 milestones. Closing expected end of fiscal 2026.

  2. ITM posts $273 million revenue

    Financial

    ITM reports US$273 million in annual revenue, a 40% compound growth rate since 2021.

  3. ITM signs supply deal with Novartis

    Business

    ITM becomes the primary external supplier of lutetium-177 for Novartis' Pluvicto, a relationship still in force.

  4. ITM founded in Munich

    Founding

    ITM Isotope Technologies Munich starts operations as a radioisotope producer and radiopharma developer.

Scenarios

1

Telix closes deal, ITM-11 wins approval for neuroendocrine tumors

Likely Resolves by End of 2027

Discussed by: Fierce Biotech; Canaccord Genuity, UBS, J.P. Morgan, and Citi analysts, all holding Buy ratings

The merger closes by end of fiscal 2026, on schedule. ITM keeps supplying Novartis and other customers while Telix integrates manufacturing, and ITM-11 wins approval for gastroenteropancreatic neuroendocrine tumors. Telix enters its first commercial therapeutic market, validating the 'moat-building' thesis that owning the isotope supply chain protects against the supply disruptions that have hit smaller radiopharma players.

2

Integration stumbles, fiscal 2027 EBITDA target slips

Possible Resolves by Q2 2028

Discussed by: TechStock 2.0 risk analysis; RBC Capital, which holds a Hold rating at A$19

The $1.65 billion price plus $302 million of assumed debt is a premium for a company that reached $273 million in 2025 revenue. If Telix struggles to fold in ITM's German operations, the projected EBITDA-positive result for fiscal 2027 slips, and the roughly 105.8 million newly issued shares dilute earnings. RBC's cautious $19 target reflects this integration risk.

3

ITM-11 milestones stall, contingent payments shrink

Possible Resolves by Q2 2027

Discussed by: Merger agreement terms; timing of the COMPOSE trial interim analysis

The $700 million in deferred consideration depends on ITM-11 hitting regulatory approval dates and an FY 2030 net sales target above $150 million. The first test is the COMPOSE trial's interim analysis, expected in the first half of 2027. If the trial misses its endpoint, or approval lags beyond the contract windows, Telix pays less and the deal's projected value weakens.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2018

Novartis acquires Advanced Accelerator Applications (2018)

Novartis paid US$3.9 billion for Advanced Accelerator Applications, a French-Italian radiopharma firm, gaining Lutathera, the first approved peptide receptor radionuclide therapy for neuroendocrine tumors.

Then

Lutathera became a commercial success and proved there was a real market for targeted radionuclide therapy.

Now

The deal drew Eli Lilly and Bristol Myers Squibb into radiopharma and made Novartis the category leader.

Why this matters now

ITM-11 is a direct competitor to Lutathera, and the Telix-ITM merger is the first serious attempt to build a vertically integrated alternative to Novartis.

October 2023

Eli Lilly acquires POINT Biopharma (2023)

Eli Lilly agreed to buy POINT Biopharma for US$1.4 billion, gaining radioligand manufacturing plants and supply-chain assets rather than just drug candidates.

Then

Lilly secured its own production capacity for experimental radioligand therapies.

Now

The deal showed that isotope supply and manufacturing, not just molecules, were the industry's real constraint.

Why this matters now

The Telix-ITM merger follows the same logic at larger scale: owning the isotope supply chain is the competitive moat.

December 2023

Bristol Myers Squibb acquires RayzeBio (December 2023)

Bristol Myers Squibb agreed to buy RayzeBio for roughly US$4.1 billion, paying a large premium for an experimental actinium-225 radioligand therapy still in Phase 3 testing.

Then

The deal signaled that pharma would pay richly for radiopharma platforms before late-stage data readouts.

Now

It set a valuation benchmark for isotope-heavy biotechs that Telix's offer for ITM is now measured against.

Why this matters now

ITM's $1.65 billion upfront price, plus $700 million in milestones, is the latest installment in a wave of radiopharma consolidation.

Sources

(11)